PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24934577-2 2014 We demonstrated an unusual case of left atrial myxoma, displaying the successful detection by positron emission tomography using 2-deoxy-2-[18 F] fluoro-D-glucose (18 F-FDG PET), correlated closely to more intense and enhanced immunoreactivity with glucose transporter-1 (GLUT-1) in a substantial number of cardiac myxoma cells. Fluorodeoxyglucose F18 129-162 solute carrier family 2 member 1 Homo sapiens 272-278 24045262-7 2013 CONCLUSIONS: In AGCs, GLUT-1 expression and Ki-67 labeling index are important factors in predicting F-FDG uptake by metastatic LNs. Fluorodeoxyglucose F18 101-106 solute carrier family 2 member 1 Homo sapiens 22-28 23701133-5 2014 2-Deoxy-2-[(18)F]-fluoro-d-glucose (FDG) uptake was significantly correlated with the levels of GLUT-1 and GLUT-3 and with IPI. Fluorodeoxyglucose F18 0-34 solute carrier family 2 member 1 Homo sapiens 96-102 23701133-5 2014 2-Deoxy-2-[(18)F]-fluoro-d-glucose (FDG) uptake was significantly correlated with the levels of GLUT-1 and GLUT-3 and with IPI. Fluorodeoxyglucose F18 36-39 solute carrier family 2 member 1 Homo sapiens 96-102 24365102-8 2014 In in vitro study, 18F-FDG uptake was markedly decreased by the inhibition of GLUT1 and GLUT1 upregulation by the induction of HIF-1alpha increased the 18F-FDG uptake. Fluorodeoxyglucose F18 19-26 solute carrier family 2 member 1 Homo sapiens 78-83 24365102-8 2014 In in vitro study, 18F-FDG uptake was markedly decreased by the inhibition of GLUT1 and GLUT1 upregulation by the induction of HIF-1alpha increased the 18F-FDG uptake. Fluorodeoxyglucose F18 19-26 solute carrier family 2 member 1 Homo sapiens 88-93 24365102-8 2014 In in vitro study, 18F-FDG uptake was markedly decreased by the inhibition of GLUT1 and GLUT1 upregulation by the induction of HIF-1alpha increased the 18F-FDG uptake. Fluorodeoxyglucose F18 152-159 solute carrier family 2 member 1 Homo sapiens 78-83 24365102-8 2014 In in vitro study, 18F-FDG uptake was markedly decreased by the inhibition of GLUT1 and GLUT1 upregulation by the induction of HIF-1alpha increased the 18F-FDG uptake. Fluorodeoxyglucose F18 152-159 solute carrier family 2 member 1 Homo sapiens 88-93 24096997-7 2013 This case suggested that Glut-3 and Glut-1 expression were facilitators of high FDG uptake in the benign gastric schwannoma. Fluorodeoxyglucose F18 80-83 solute carrier family 2 member 1 Homo sapiens 36-42 26824929-0 2013 Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation. Fluorodeoxyglucose F18 146-169 solute carrier family 2 member 1 Homo sapiens 19-40 26824929-0 2013 Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation. Fluorodeoxyglucose F18 146-169 solute carrier family 2 member 1 Homo sapiens 42-47 22901702-12 2012 CONCLUSIONS: The data in this preliminary study indicate that FDG uptake in malignant melanoma is determined by GLUT-1 and GLUT-3, whereas HK-2 and Ki-67 play no role in FDG uptake of malignant melanoma. Fluorodeoxyglucose F18 62-65 solute carrier family 2 member 1 Homo sapiens 112-118 23699745-0 2013 Glucose transporter-1 distribution in fibrotic lung disease: association with [18F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. Fluorodeoxyglucose F18 84-107 solute carrier family 2 member 1 Homo sapiens 0-21 23674658-0 2013 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1alpha, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Fluorodeoxyglucose F18 0-22 solute carrier family 2 member 1 Homo sapiens 182-203 24899993-1 2011 The expression of glucose transporters (Glut-1, Glut-3), hexokinase-II, and Ki-67 has been proposed to explain intratumoral heterogeneous F-18 fluorodeoxyglucose (FDG) uptake. Fluorodeoxyglucose F18 163-166 solute carrier family 2 member 1 Homo sapiens 40-46 22408261-7 2012 Furthermore, the effect of panobinostat on GLUT1 expression suggests that panobinostat may modulate the results of clinical diagnostic imaging tests that depend of functional GLUT1, such as fluorodeoxyglucose positron emission tomography. Fluorodeoxyglucose F18 190-208 solute carrier family 2 member 1 Homo sapiens 43-48 22408261-7 2012 Furthermore, the effect of panobinostat on GLUT1 expression suggests that panobinostat may modulate the results of clinical diagnostic imaging tests that depend of functional GLUT1, such as fluorodeoxyglucose positron emission tomography. Fluorodeoxyglucose F18 190-208 solute carrier family 2 member 1 Homo sapiens 175-180 22398711-0 2012 Correlation between FDG uptake by PET/CT and the expressions of glucose transporter type 1 and hexokinase II in cervical cancer. Fluorodeoxyglucose F18 20-23 solute carrier family 2 member 1 Homo sapiens 64-90 24900002-11 2011 CONCLUSION: Lymphoid follicular hyperplasia and histiocyte infiltration associated with Glut1 overexpression are important molecular and pathological mechanisms for false-positive FDG uptake in benign mediastinal LNs in patients with NSCLC. Fluorodeoxyglucose F18 180-183 solute carrier family 2 member 1 Homo sapiens 88-93 20884076-1 2011 PURPOSE: The objective of this study was to evaluate the major factors influencing on FDG uptake in non-small cell lung cancer (NSCLC) by investigating histological difference in the expression of glucose transporters 1 and 3 (Glut-1 and Glut-3) and tumour size. Fluorodeoxyglucose F18 86-89 solute carrier family 2 member 1 Homo sapiens 227-233 20646779-7 2011 There were positive correlation between 18F-FDG uptake and Glut1 (p=0.0016), Glut3 (p=0.0080), VEGF (p=0.0048), and microvessel density (MVD) (p=0.0005). Fluorodeoxyglucose F18 40-47 solute carrier family 2 member 1 Homo sapiens 59-64 20703861-0 2010 Correlation between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Fluorodeoxyglucose F18 57-82 solute carrier family 2 member 1 Homo sapiens 20-41 19173807-1 2008 OBJECTIVE: To investigate the correlation between 18F-FDG standard uptake value (SUV) and expression of GLUT1, MVD and Ki67 in non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 50-57 solute carrier family 2 member 1 Homo sapiens 104-109 20145577-8 2010 RESULTS: In a multivariate linear regression model, GLUT-1, CD68, cathepsin K, and HK2 gene expression remained in the final model as predictive variables of FDG accumulation calculated as SUVmean (R=0.26, P<0.0001). Fluorodeoxyglucose F18 158-161 solute carrier family 2 member 1 Homo sapiens 52-58 20145577-10 2010 CONCLUSION: GLUT-1, HK2, CD68, and cathepsin K remained in both multivariate models and thus provided independent information regarding FDG uptake. Fluorodeoxyglucose F18 136-139 solute carrier family 2 member 1 Homo sapiens 12-18 20204293-17 2010 Immunohistochemical examination of GLUT-1 confirmed the high FDG uptake in LMS patients. Fluorodeoxyglucose F18 61-64 solute carrier family 2 member 1 Homo sapiens 35-41 19408578-3 2009 Thus, we investigated the relationship of FDG uptake and the expressions of glucose transporter type 1 (Glut-1), glucose transporter type 3 (Glut-3), and hexokinase II (HK-II) in R-S cells of HL. Fluorodeoxyglucose F18 42-45 solute carrier family 2 member 1 Homo sapiens 104-110 18982472-0 2008 Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Fluorodeoxyglucose F18 20-23 solute carrier family 2 member 1 Homo sapiens 41-46 18982472-7 2008 RESULTS: The pleomorphic adenomas stained positively for GLUT1, and there was significant correlation between the GLUT1 index and the SUV in FDG-PET. Fluorodeoxyglucose F18 141-144 solute carrier family 2 member 1 Homo sapiens 114-119 18982472-10 2008 This result suggests that GLUT1 plays an important role in increasing FDG uptake in salivary gland pleomorphic adenomas. Fluorodeoxyglucose F18 70-73 solute carrier family 2 member 1 Homo sapiens 26-31 20540786-0 2010 The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. Fluorodeoxyglucose F18 37-40 solute carrier family 2 member 1 Homo sapiens 108-114 19536037-12 2009 CONCLUSION: Intensity of lymphoma on FDG PET is likely associated with Glut1 expression. Fluorodeoxyglucose F18 37-40 solute carrier family 2 member 1 Homo sapiens 71-76 18979289-0 2008 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Fluorodeoxyglucose F18 27-30 solute carrier family 2 member 1 Homo sapiens 92-98 19317609-4 2008 The correlation between FDG uptake and the expression of Glut in various tumor cells is still under debate. Fluorodeoxyglucose F18 24-27 solute carrier family 2 member 1 Homo sapiens 57-61 20735969-0 2008 [Relationship between Glut-1, Glut-3 expression and fluorodeoxyglucose uptake in NSCLC and benign pulmonary lesion.]. Fluorodeoxyglucose F18 52-70 solute carrier family 2 member 1 Homo sapiens 22-28 17080242-0 2006 Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Fluorodeoxyglucose F18 77-107 solute carrier family 2 member 1 Homo sapiens 15-21 17653575-9 2008 In contrast, a significant correlation was found between 18FDG uptake and Glut-1 expression. Fluorodeoxyglucose F18 57-62 solute carrier family 2 member 1 Homo sapiens 74-80 17653575-13 2008 CONCLUSIONS: Glut-1 expression and tumour size seem parameters associated with 18FDG uptake in patients with biopsy proven oesophageal adenocarcinoma, and may be used to select oesophageal cancer patients in whom 18FDG-PET is of diagnostic value and may predict disease outcome. Fluorodeoxyglucose F18 79-84 solute carrier family 2 member 1 Homo sapiens 13-19 17640764-7 2008 The specificity of the liver 18FDG uptake was confirmed by Glut-1 positive immunostaining. Fluorodeoxyglucose F18 29-34 solute carrier family 2 member 1 Homo sapiens 59-65 16115558-10 2005 Neither area reacted with glucose transporter-1 (GLUT-1), correlating with low FDG-PET uptake. Fluorodeoxyglucose F18 79-82 solute carrier family 2 member 1 Homo sapiens 49-55 16506050-0 2006 Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Fluorodeoxyglucose F18 150-168 solute carrier family 2 member 1 Homo sapiens 0-6 16595493-7 2006 In untreated MCF-7 cells, the mRNA levels of HKII were typically higher than those of Glut-1, and (3)H-FDG uptake was strongly related to Glut-1 mRNA expression (R(2) = 0.85). Fluorodeoxyglucose F18 103-106 solute carrier family 2 member 1 Homo sapiens 138-144 17294670-0 2006 Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Fluorodeoxyglucose F18 14-45 solute carrier family 2 member 1 Homo sapiens 161-182 17294670-3 2006 The aim of the present study is to clarify FDG uptake in gastric carcinomas especially focusing on histological subtypes, the depth of tumor invasion, and glucose transporter-1 (GLUT-1) expression which is considered to be one of the major factors for higher FDG uptake in human malignant tumors. Fluorodeoxyglucose F18 43-46 solute carrier family 2 member 1 Homo sapiens 155-176 17294670-3 2006 The aim of the present study is to clarify FDG uptake in gastric carcinomas especially focusing on histological subtypes, the depth of tumor invasion, and glucose transporter-1 (GLUT-1) expression which is considered to be one of the major factors for higher FDG uptake in human malignant tumors. Fluorodeoxyglucose F18 43-46 solute carrier family 2 member 1 Homo sapiens 178-184 17294670-3 2006 The aim of the present study is to clarify FDG uptake in gastric carcinomas especially focusing on histological subtypes, the depth of tumor invasion, and glucose transporter-1 (GLUT-1) expression which is considered to be one of the major factors for higher FDG uptake in human malignant tumors. Fluorodeoxyglucose F18 259-262 solute carrier family 2 member 1 Homo sapiens 155-176 17294670-3 2006 The aim of the present study is to clarify FDG uptake in gastric carcinomas especially focusing on histological subtypes, the depth of tumor invasion, and glucose transporter-1 (GLUT-1) expression which is considered to be one of the major factors for higher FDG uptake in human malignant tumors. Fluorodeoxyglucose F18 259-262 solute carrier family 2 member 1 Homo sapiens 178-184 17294670-10 2006 GLUT-1 expression was the most influential factor for the degree of FDG uptake in gastric carcinoma (R2 = 0.68). Fluorodeoxyglucose F18 68-71 solute carrier family 2 member 1 Homo sapiens 0-6 15061260-1 2004 To clarify the biological significance of [18F]fluorodeoxyglucose (18F-FDG) accumulation in patients with cancer, we assessed the relationships between 18F-FDG uptake and glucose transporter-1 (GLUT-1) expression and proliferation rate in human glioma and lung cancer. Fluorodeoxyglucose F18 67-74 solute carrier family 2 member 1 Homo sapiens 194-200 15363231-1 2004 OBJECTIVE: To assess the relationship between the overexpression of facilitative glucose transporter-1 (Glut1) and fluorine-18 fluorodeoxyglucose (FDG) uptake in patients with primary lung adenocarcinoma. Fluorodeoxyglucose F18 115-145 solute carrier family 2 member 1 Homo sapiens 104-109 15363231-1 2004 OBJECTIVE: To assess the relationship between the overexpression of facilitative glucose transporter-1 (Glut1) and fluorine-18 fluorodeoxyglucose (FDG) uptake in patients with primary lung adenocarcinoma. Fluorodeoxyglucose F18 147-150 solute carrier family 2 member 1 Homo sapiens 104-109 15363231-11 2004 CONCLUSION: Glut1 overexpression is universal in the lung adenocarcinoma and correlate with FDG uptake. Fluorodeoxyglucose F18 92-95 solute carrier family 2 member 1 Homo sapiens 12-17 15695798-0 2005 Nitric oxide stimulates 18F-FDG uptake in human endothelial cells through increased hexokinase activity and GLUT1 expression. Fluorodeoxyglucose F18 28-31 solute carrier family 2 member 1 Homo sapiens 108-113 9476929-1 1998 UNLABELLED: Fluorine-18-fluorodeoxyglucose (FDG) is used clinically for tumor diagnosis, but its mechanism of accumulation in tumor cells is complicated because two factors, glucose transporter protein (GLUT) and hexokinase, govern [18F]FDG uptake directly. Fluorodeoxyglucose F18 12-42 solute carrier family 2 member 1 Homo sapiens 203-207 12926062-0 2003 Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Fluorodeoxyglucose F18 15-38 solute carrier family 2 member 1 Homo sapiens 84-90 12926062-0 2003 Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Fluorodeoxyglucose F18 40-43 solute carrier family 2 member 1 Homo sapiens 84-90 12932118-4 2003 An immunohistochemical analysis demonstrated a high GLUT-1 expression in the right cervical lymph node, which showed a high FDG uptake. Fluorodeoxyglucose F18 124-127 solute carrier family 2 member 1 Homo sapiens 52-58 14728832-1 2003 OBJECTIVE: To assess the relationship between the overexpression of facilitative glucose transporter-1 (Glut1) and fluorine-18 fluorodeoxyglucose (FDG) uptake in patients with primary lung squamous cell carcinoma. Fluorodeoxyglucose F18 115-145 solute carrier family 2 member 1 Homo sapiens 104-109 14728832-1 2003 OBJECTIVE: To assess the relationship between the overexpression of facilitative glucose transporter-1 (Glut1) and fluorine-18 fluorodeoxyglucose (FDG) uptake in patients with primary lung squamous cell carcinoma. Fluorodeoxyglucose F18 147-150 solute carrier family 2 member 1 Homo sapiens 104-109 12325075-1 2002 Cerebral 18F-fluorodeoxyglucose positron emission tomography in 14 patients with microcephaly, developmental delay, seizures, and mutations of the glucose transporter Glut1 (Glut1 deficiency syndrome) showed distinct abnormalities. Fluorodeoxyglucose F18 9-31 solute carrier family 2 member 1 Homo sapiens 167-172 10493529-0 1999 Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Fluorodeoxyglucose F18 52-78 solute carrier family 2 member 1 Homo sapiens 0-21 9804039-1 1998 Glucose transporter (GLUT) expression and hexokinase activity are thought to be related to high [18F]-fluorodeoxyglucose (FDG) uptake in tumor cells, but their relative importance is still unknown. Fluorodeoxyglucose F18 96-120 solute carrier family 2 member 1 Homo sapiens 0-19 9804039-1 1998 Glucose transporter (GLUT) expression and hexokinase activity are thought to be related to high [18F]-fluorodeoxyglucose (FDG) uptake in tumor cells, but their relative importance is still unknown. Fluorodeoxyglucose F18 96-120 solute carrier family 2 member 1 Homo sapiens 21-25 9804039-1 1998 Glucose transporter (GLUT) expression and hexokinase activity are thought to be related to high [18F]-fluorodeoxyglucose (FDG) uptake in tumor cells, but their relative importance is still unknown. Fluorodeoxyglucose F18 122-125 solute carrier family 2 member 1 Homo sapiens 0-19 9804039-1 1998 Glucose transporter (GLUT) expression and hexokinase activity are thought to be related to high [18F]-fluorodeoxyglucose (FDG) uptake in tumor cells, but their relative importance is still unknown. Fluorodeoxyglucose F18 122-125 solute carrier family 2 member 1 Homo sapiens 21-25 9476929-1 1998 UNLABELLED: Fluorine-18-fluorodeoxyglucose (FDG) is used clinically for tumor diagnosis, but its mechanism of accumulation in tumor cells is complicated because two factors, glucose transporter protein (GLUT) and hexokinase, govern [18F]FDG uptake directly. Fluorodeoxyglucose F18 44-47 solute carrier family 2 member 1 Homo sapiens 203-207 9293783-11 1997 CONCLUSION: These data indicate that GLUT-1 has a significant role in the malignant glucose metabolism and may contribute to the increased uptake of FDG in PET imaging in patients with pancreatic tumor. Fluorodeoxyglucose F18 149-152 solute carrier family 2 member 1 Homo sapiens 37-43 34422129-4 2021 All thymomas show some degree of 18F-FDG uptake, which tends to increase with the grade of malignancy; this is related to glucose transporter 1 (GLUT1) expression. Fluorodeoxyglucose F18 33-40 solute carrier family 2 member 1 Homo sapiens 145-150 34572860-3 2021 We retrospectively analyzed the following three points in 84 patients with IPMNs: (1) risk factors to predict high-grade dysplasia (HGD) and invasive carcinoma (INV); (2) the relationship between FDG uptake and glucose transporter 1 (GLUT-1) expression; and (3) the relationship between FDG uptake and the presence of mural nodules. Fluorodeoxyglucose F18 196-199 solute carrier family 2 member 1 Homo sapiens 211-232 34572860-3 2021 We retrospectively analyzed the following three points in 84 patients with IPMNs: (1) risk factors to predict high-grade dysplasia (HGD) and invasive carcinoma (INV); (2) the relationship between FDG uptake and glucose transporter 1 (GLUT-1) expression; and (3) the relationship between FDG uptake and the presence of mural nodules. Fluorodeoxyglucose F18 196-199 solute carrier family 2 member 1 Homo sapiens 234-240 32886301-12 2021 Ex vivo VAT [18F]FDG uptake was positively related to GLUT4 (r = 0.83, p = 0.042), inversely to GLUT3 (r = - 0.83, p = 0.042) and not related to GLUT1 mRNA expression levels. Fluorodeoxyglucose F18 17-20 solute carrier family 2 member 1 Homo sapiens 145-150 34049629-2 2021 Therefore, GLUT1-targeted oncological approaches are being successfully employed for clinical tumor diagnostic imaging (e.g. the 18F-FDG/PET), drug delivery and novel anticancer drug development. Fluorodeoxyglucose F18 129-136 solute carrier family 2 member 1 Homo sapiens 11-16 33725499-12 2021 CONCLUSION: HRD1 inhibits the high uptake of [18F]FDG in HCC tumor cells by inducing degradation of GLUT1, which leads to decreased diagnostic efficiency of [18F]FDG PET imaging for HCC. Fluorodeoxyglucose F18 50-53 solute carrier family 2 member 1 Homo sapiens 100-105 33725499-12 2021 CONCLUSION: HRD1 inhibits the high uptake of [18F]FDG in HCC tumor cells by inducing degradation of GLUT1, which leads to decreased diagnostic efficiency of [18F]FDG PET imaging for HCC. Fluorodeoxyglucose F18 162-165 solute carrier family 2 member 1 Homo sapiens 100-105 33725499-13 2021 ADVANCES IN KNOWLEDGE: This study suggests that HRD1 inhibits the high uptake of [18F]FDG in HCC tumor by inducing degradation of GLUT1. Fluorodeoxyglucose F18 86-89 solute carrier family 2 member 1 Homo sapiens 130-135 33750337-11 2021 The expression of GLUT-1 and MACC1 was associated with 18F-FDG uptake in CRC patients. Fluorodeoxyglucose F18 55-62 solute carrier family 2 member 1 Homo sapiens 18-24 32626532-10 2020 GLUT1 and HK2 expression in ESCA was positively correlated with 18F-FDG uptake and METTL3 status (p < 0.001). Fluorodeoxyglucose F18 64-71 solute carrier family 2 member 1 Homo sapiens 0-5 32739099-1 2021 PURPOSE: To establish an objective method of [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) that can assist in the diagnosis of glucose transporter 1 deficiency syndrome (GLUT1-DS). Fluorodeoxyglucose F18 49-69 solute carrier family 2 member 1 Homo sapiens 188-193 33278334-0 2021 Tyrosine kinase inhibitors reduce glucose uptake by binding to an exofacial site on hGLUT-1: Effects on 18 F-FDG PET uptake. Fluorodeoxyglucose F18 104-112 solute carrier family 2 member 1 Homo sapiens 84-91 33278334-3 2021 We evaluated the interaction of several classes of TKIs with human glucose transporter-1 (hGLUT-1) in FaDu and GIST-1 cells by measuring [3 H]2-deoxy-D-glucose ([3 H]2-DG) and [3 H]FDG uptake. Fluorodeoxyglucose F18 181-184 solute carrier family 2 member 1 Homo sapiens 90-97 33278334-10 2021 hGLUT-1 inhibition by TKIs may have implications for routine [18 F]FDG-PET monitoring of tumor response in patients. Fluorodeoxyglucose F18 67-70 solute carrier family 2 member 1 Homo sapiens 0-7 32626532-11 2020 Conclusions: The high expression of METTL3 is related to the high SUVmax in ESCA, and METTL3 may increase 18F-FDG uptake by regulating GLUT1 and HK2. Fluorodeoxyglucose F18 106-113 solute carrier family 2 member 1 Homo sapiens 135-140 32028659-2 2020 Glucose transporter 1 (GLUT1), in particular, plays an important role in the mechanism of 18F-FDG (2-[18F]-fluoro-2-deoxy-d-glucose) within tumor cells. Fluorodeoxyglucose F18 90-97 solute carrier family 2 member 1 Homo sapiens 0-21 32269845-6 2020 Microscopic and immunohistochemical investigations were performed to confirm tumor growth and correlate the glycolysis markers glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) with FDG uptake. Fluorodeoxyglucose F18 185-188 solute carrier family 2 member 1 Homo sapiens 127-148 32269845-6 2020 Microscopic and immunohistochemical investigations were performed to confirm tumor growth and correlate the glycolysis markers glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) with FDG uptake. Fluorodeoxyglucose F18 185-188 solute carrier family 2 member 1 Homo sapiens 150-155 32028659-2 2020 Glucose transporter 1 (GLUT1), in particular, plays an important role in the mechanism of 18F-FDG (2-[18F]-fluoro-2-deoxy-d-glucose) within tumor cells. Fluorodeoxyglucose F18 90-97 solute carrier family 2 member 1 Homo sapiens 23-28 31186081-0 2019 ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway. Fluorodeoxyglucose F18 32-50 solute carrier family 2 member 1 Homo sapiens 95-100 31271267-2 2021 To assess FDG uptake in small bowel adenocarcinoma, we retrospectively analyzed a large, single-center database and determined the expression of glucose-transporter type 1 (GLUT-1). Fluorodeoxyglucose F18 10-13 solute carrier family 2 member 1 Homo sapiens 173-179 30682160-3 2019 Here, we present both in vitro and small animal in vivo imaging evidence that the high physiological expression of the glucose transporter GLUT1 on human erythrocytes allows uptake of the widely available radiotracer 2-deoxy-2-(18F)fluoro-D-glucose (FDG), at a rate and magnitude sufficient for clinical blood pool positron emission tomographic (PET) imaging. Fluorodeoxyglucose F18 217-248 solute carrier family 2 member 1 Homo sapiens 139-144 30682160-3 2019 Here, we present both in vitro and small animal in vivo imaging evidence that the high physiological expression of the glucose transporter GLUT1 on human erythrocytes allows uptake of the widely available radiotracer 2-deoxy-2-(18F)fluoro-D-glucose (FDG), at a rate and magnitude sufficient for clinical blood pool positron emission tomographic (PET) imaging. Fluorodeoxyglucose F18 250-253 solute carrier family 2 member 1 Homo sapiens 139-144 30431083-0 2019 EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Fluorodeoxyglucose F18 24-27 solute carrier family 2 member 1 Homo sapiens 82-87 30799682-10 2019 FASN was highly expressed in cell lines with high 18F-FPA uptake, whereas GLUT1 was highly expressed in cell lines with high 18F-FDG uptake. Fluorodeoxyglucose F18 125-132 solute carrier family 2 member 1 Homo sapiens 74-79 29550845-9 2018 CONCLUSION: Glucose transporter-1, estrogen receptor alpha negativity and nuclear grade might affect the high 18F-FDG uptake in breast cancer. Fluorodeoxyglucose F18 110-117 solute carrier family 2 member 1 Homo sapiens 12-33 30864374-4 2018 As the current standard positron emission tomography (PET) tracer 2-deoxy-2-(18F)fluoro-D-glucose (2-FDG) for imaging tumour cells via GLUT1 lacks in sensitivity and specificity, it may soon be replaced by the newly designed, highly sensitive and specific SGLT tracer alpha-methyl-4-(F-18)fluoro-4-deoxy-Dglucopyranoside (Me-4FDG) in clinical detection and tumour staging. Fluorodeoxyglucose F18 66-97 solute carrier family 2 member 1 Homo sapiens 135-140 30864374-4 2018 As the current standard positron emission tomography (PET) tracer 2-deoxy-2-(18F)fluoro-D-glucose (2-FDG) for imaging tumour cells via GLUT1 lacks in sensitivity and specificity, it may soon be replaced by the newly designed, highly sensitive and specific SGLT tracer alpha-methyl-4-(F-18)fluoro-4-deoxy-Dglucopyranoside (Me-4FDG) in clinical detection and tumour staging. Fluorodeoxyglucose F18 99-104 solute carrier family 2 member 1 Homo sapiens 135-140 29913554-1 2018 Elevated growth in breast cancer (BC) activates hypoxia-inducible factor (HIF1alpha) and downstream, facilitative glucose transporter 1 (GLUT1), which can be visualized with 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG). Fluorodeoxyglucose F18 174-205 solute carrier family 2 member 1 Homo sapiens 137-142 30083516-7 2018 PET revealed significantly higher relative uptake of 18F-FDG in the CALR cohort, which was associated with significantly greater Glut-1 expression. Fluorodeoxyglucose F18 53-60 solute carrier family 2 member 1 Homo sapiens 129-135 28548087-5 2017 Clinically, elevated GLUT1-mediated glycolysis in lung SqCC strongly correlates with high 18F-FDG uptake and poor prognosis. Fluorodeoxyglucose F18 90-97 solute carrier family 2 member 1 Homo sapiens 21-26 28412205-2 2017 Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. Fluorodeoxyglucose F18 203-225 solute carrier family 2 member 1 Homo sapiens 104-110 28412205-2 2017 Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. Fluorodeoxyglucose F18 203-225 solute carrier family 2 member 1 Homo sapiens 111-116 28412205-2 2017 Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. Fluorodeoxyglucose F18 227-234 solute carrier family 2 member 1 Homo sapiens 104-110 28412205-2 2017 Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. Fluorodeoxyglucose F18 227-234 solute carrier family 2 member 1 Homo sapiens 111-116 28410229-3 2017 We explored whether the expression of HIF-1alpha and GLUT-1 was correlated with 2"-deoxy-2"-[18F]fluoro-D-glucose (18F-FDG) uptake and whether 18F-FDG positron emission tomography-computed tomography (PET/CT) was appropriate for early evaluation of the response of laryngeal carcinoma to targeted treatment in vivo. Fluorodeoxyglucose F18 80-113 solute carrier family 2 member 1 Homo sapiens 53-59 28410229-3 2017 We explored whether the expression of HIF-1alpha and GLUT-1 was correlated with 2"-deoxy-2"-[18F]fluoro-D-glucose (18F-FDG) uptake and whether 18F-FDG positron emission tomography-computed tomography (PET/CT) was appropriate for early evaluation of the response of laryngeal carcinoma to targeted treatment in vivo. Fluorodeoxyglucose F18 115-122 solute carrier family 2 member 1 Homo sapiens 53-59 27347132-3 2016 However, the association between GLUT-1 expression and clinicopathological factors, 18F-fluorodeoxyglucose uptake and tumor proliferation in pancreatic cancer has not been investigated to date. Fluorodeoxyglucose F18 84-106 solute carrier family 2 member 1 Homo sapiens 33-39 27218430-8 2016 GLUT-1, GLUT-3, MVD, and TAMs are associated with the mechanism of F-FDG uptake in ESCC. Fluorodeoxyglucose F18 67-72 solute carrier family 2 member 1 Homo sapiens 0-6 27173341-1 2016 The purpose of this study was to investigate the association between cellular 2-deoxy-2-[18F]-fluoro-D-glucose ((18)F-FDG) uptake and the expression of several subtypes of glucose transporters (GLUT) and Ki-67 in diffuse large B-cell lymphoma (DLBCL) and natural killer (NK)/T-cell lymphoma (NKTCL). Fluorodeoxyglucose F18 78-110 solute carrier family 2 member 1 Homo sapiens 194-198 25307508-2 2015 In ovarian cancer, glucose transporter 1 (GLUT1) is overexpressed and positron emission tomography (PET) using [18(F)] fluorodeoxyglucose (FDG), as a metabolic tumor parameter, has been found to be an effective diagnostic tool. Fluorodeoxyglucose F18 119-137 solute carrier family 2 member 1 Homo sapiens 42-47